IBM enters the back half of April nursing a sharp post-earnings wound — a 9.6% single-day drop on April 22 that analysts are still trying to price around.
The week's central tension is straightforward: results disappointed badly enough to spark widespread target cuts, yet the stock remains well above where short sellers are actually positioned, and the lending market shows no sign of fresh conviction on the downside.
The Q1 print on April 22 was the defining event. IBM fell 9.6% that day and extended the loss to 11.2% over the following five sessions. The stock closed Wednesday at $227.10, down almost 10% on the week and roughly 28% below its 90-day high of $314.73. The Consulting segment took the brunt of investor concern — currency headwinds and macro caution were the cited culprits — while the software business offered only partial offset. The next catalyst is not until July 22, when IBM reports Q2.
Short interest does not tell a story of bears piling in after the miss. Short interest as a percentage of free float actually fell through the week, easing from 2.5% on April 22 to 2.3% by April 28 — a seven-week low. Borrow costs remain negligible at 0.53% APR, roughly unchanged on the week, and availability in the lending market is loose. There is no squeeze dynamic here, and the data suggests shorts have been using the post-earnings dislocation to cover, not build. The ORTEX short score has also drifted lower, from 35.8 to 34.0 over the past week, confirming that bearish pressure from the borrow market is fading rather than intensifying.
Options positioning hints at a mild shift in tone. The put/call ratio at 0.81 is actually running just below its 20-day average of 0.83 — marginally less defensive than usual, which is a mild surprise given the magnitude of the price drop. The z-score of -1.0 suggests call activity is fractionally elevated relative to recent norms. Either traders are buying the dip in calls, or the put-buying wave after earnings has already faded. The 52-week range for the PCR runs from 0.62 to 1.07, so the current reading is comfortably mid-range — neither a bearish pile-on nor an aggressive bull signal.
The analyst reaction has been a consistent ratchet down in price targets with underlying ratings broadly intact. Morgan Stanley, maintaining its Equal-Weight stance, nudged its target up slightly to $225 — effectively a call that the stock has reached fair value at current levels. The more bullish shops — Wedbush, Evercore, Jefferies, RBC, and Oppenheimer — all trimmed targets meaningfully, with cuts ranging from $20 to $60, but every one of them kept their positive ratings. The one genuine upgrade came from HSBC, which moved IBM to Hold from Reduce and lifted its target to $231 — a move that looks more like capitulation than conviction. The Street mean target stands at $279.68, implying roughly 23% upside from $227. The analyst recommendation differential ranks in the 98th percentile, meaning the Street's rating is unusually favourable relative to peers, even after all the cuts.
On valuation, IBM now trades at a P/E around 17.8x and an EV/EBITDA of 12.5x — both have compressed about 7-8% over the past week as the stock fell. The P/B has also slipped to 5.3x. None of these are distressed multiples for a business growing software at mid-to-high single digits, and the bull case rests on that software flywheel: Red Hat, hybrid cloud, and an AI consulting pipeline that management insists is building. The bear case centres on the Consulting drag, FX headwinds of over $1 billion in projected revenue impact, and displacement risk from code-generation AI eroding legacy integration work.
Institutional ownership is dominated by passive giants — Vanguard at 10.3%, BlackRock at 8.3%, State Street at 5.9% — so forced selling is unlikely. Capital Research added over 5 million shares as of March 31, a constructive move made before the earnings drop that may bear watching in the next quarterly filing. Insider activity from February was routine: a handful of small open-market buys from directors at around $235-237, and standard award-and-sell cycles from the CFO and executive vice chairman. Nothing there changed the narrative.
The post-earnings pattern is now well-established: IBM dropped heavily on the print, shorts have been covering rather than adding, and the analyst community is recalibrating price targets while holding its positive ratings. The next read on whether the Consulting business has stabilised or deteriorated further comes with Q2 results on July 22.
See the live data behind this article on ORTEX.
Open IBM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
